Skip to main content
OpenTrials
Completed

NCT Number: NCT00263575

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.

Completed

Looking for future studies?

Notify Me

Key information

Age range

17 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Carolinas Pain Institute

Winston-Salem, North Carolina, 27103, United States

About this study

This was a Phase 3 non-randomized, open-label, multicentre study designed to evaluate the long-term safety of EN3267 in the treatment of BTcP in opioid-tolerant cancer patients. The study was conducted in 2 parts:

  • A Titration Period during which patients had up to 2 weeks to determine a single, effective dose of study medication (EN3267) for adequate treatment of BTcP, and
  • A maintenance Period of up to 12 months in which episodes of BTcP were treated with study medication.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or females 17 years of age or older.
  • Stable cancer-related pain.
  • Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain.
  • Experiencing 1-4 episodes of breakthrough pain per day.
  • Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.

Exclusion criteria

  • Have previously been exposed to EN3267.
  • Are pregnant or lactating.
  • Have uncontrolled or rapidly escalating pain.
  • Have any clinically significant condition that would, in the investigator's opinion, preclude participation in the study or compromise data collection. These conditions may include cardiopulmonary disease, and/or neurologic/psychologic conditions.
  • Are scheduled to take MAOIs (monoamine oxidase inhibitors) during the study.
  • Are scheduled to receive anti-neoplastic therapy that, in the investigator's opinion, will influence assessment of breakthrough pain.
  • Are scheduled to receive an investigational drug other than EN3267 during the course of the study.
  • Have hypersensitivity, allergy or contraindication to fentanyl.
  • Have significant prior history of substance abuse or alcohol abuse.
  • Would have difficulty complying with the protocol, as assessed by the investigator.
  • Are unable to read, write, or comprehend the English language in order to complete diaries.

Treatment and study plan

EN3267

Drug

EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses

Other names: Fentanyl

Primary outcomes

  1. Evaluate the Long-term Safety and Effectiveness of EN3267

    Time frame: screening, 2 week titration period and 12 monthly study visits

Sponsors and collaborators

Lead sponsor

Kyowa Kirin Co., Ltd.

Industry

Registry information

Official study title

A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients

Important dates

Study start
2005
Primary completion
2008
Study completion
2009
First posted
Dec 9, 2005
Registry last updated
Jun 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.